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and intensity relative numbers. Results: In 2002, a total of 151,220 members were 
registered in 35 funds, increasing to 1,033,615 members in 31 funds by 2013. The 
total revenue of the health funds was HUF 6.699 billion in 2002, HUF 35.097 billion 
in 2007, and HUF 50.923 billion in 2013. The distribution of health fund payments 
as a percentage of consumption showed: in 2007, 88.4% supplementary health 
insurance services, including 16% supplementary services within the framework 
of social security benefits, 77% self-care services provided by the health funds (67.1% 
medicine, 31.2% medical device), while in 2013, 98.2% supplementary health insur-
ance services, including 18.6% supplementary services within the framework of 
social security benefits, 80.7% self-care services provided by the health funds (71.2% 
medicine, 28% medical device). Health fund payments for lifestyle improvement 
services reached 11.6% in 2007, and 1.5% in 2013. ConClusions: Reduction in the 
number of health funds, and an increase both in membership and revenues indicate 
the consolidation of the function of health funds. The distribution of payments 
by consumption shows no significant progress: medicine and medical device still 
play a major role, and disease prevention and health care services still represent 
a very small proportion.
PHP170
WHen can PHarmaceutical comPanies communicate HealtH 
economic claims to Payers? 10 case studies
Neumann P.J.1, Saret C.J.2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health 
Policy Studies, Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and 
Risk in Health, Tufts Medical Center, Boston, MA, USA
objeCtives: In the United States, Section 114 of the Food and Drug Modernization 
Act of 1997 (FDAMA) governs pharmaceutical companies’ promotion of health 
economic information to payers. Research shows that while payers frequently 
seek cost-effectiveness information, drug companies may hesitate to promote 
it because the law is unclear. The Food and Drug Administration (FDA) has not 
offered further guidance, although it suggested that it plans to publish draft guid-
ance in 2015. We developed hypothetical case studies of promotional claims and 
explored key questions about whether the FDA would allow them under Section 
114. Methods: We created ten categories of potential claims: 1) Costing out on-
label clinical endpoints, 2) Promotion of a costing exercise to physicians working in 
an accountable care organization settings, 3) Burden of illness claims, 4) Economic 
analyses of a formulary restriction policy, 5) Extrapolations to doses, populations, 
or settings not covered in trials, 6) Adherence claims, 7) “Utilization of care” as 
a secondary endpoint in randomized clinical trials, 8) Costing out a competitor 
drug’s adverse event, 9) Economic analysis of comparative effectiveness claims 
using an indirect treatment comparison, and 10) Extrapolating from surrogate to 
long-term outcomes in an economic model. We developed a case study for each. 
We sought to balance examples across diseases and to address the components 
of Section 114: information type, connection to labeled indication, audience, and 
evidence quality. Results: Most cases fall into a “gray area” as to whether they are 
allowable under Section 114. In particular, there is a lack of clarity about whether 
claims meet requirements that they be “directly related” to approved indications 
and supported by “competent and reliable scientific evidence.” ConClusions: 
This study reinforces the need for further guidance and/or legislation to clarify 
and possibly expand the Section. It also illustrates challenges the FDA faces in 
regulating this area.
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objeCtives: There is a perception that the National Institute of Health and Care 
Excellence (NICE) has struggled to get clinical commissioning groups (CCGs) to 
follow guidelines. There is a legal obligation to follow NICE technology appraisal 
guidance (TAG) when these are accompanied by a funding direction; however it 
has long been considered that this was not the case for Clinical Guidelines (CGs) 
nor is there any right of appeal in relation to CGs. We seek to demonstrate that 
CGs could be effectively mandatory unless a reasoned justification is provided. 
The position is contrasted with respect to guidance from technology apprais-
als. Methods: Case law and legislation are reviewed to compare the enforce-
ability of general guidelines and health technology appraisal-derived guidance. 
In particular Regina vs. North Derbyshire Health Authority, ex parte Fisher (1997) 
(Regina), and the recent decision of Rose vs. Thanet CCG (Rose) are referred to. 
We review both the CGs and TAGs issued and compare the strength and range of 
the recommendations. Results: The Reginacase established that a decision not 
to follow national policy was only lawful if there was some ‘special factor’, which 
‘exceptionally justified departure’. Disagreement with the policy was not enough. 
Following this, the recent Rose case considered that the CCG was under an implied 
obligation to give reasons for any general policy not to fund a particular inter-
vention, which suggests that the guidance is effectively mandatory unless there 
are special grounds. ConClusions: Even if the Rose decision were successfully 
appealed or distinguishable, CCGs will need to consider special circumstances if 
they do not wish to implement a CG. Along with financial constraints on health 
budgets, this creates dilemmas for CCGs including local priority setting. Therefore, 
as the law stands, exceptional circumstances will need to be identified by CCGs 
taking a contrary decision to a CG.
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sion, and 35% of them prefer to perform nutrition assessment during hospitaliza-
tion. ConClusions: Inappropriate nutrition care from healthcare providers was 
possibly due to the lack of appropriate guidelines and insufficient knowledge. 
Special nutrition management trainings and continuing professional develop-
ment (CPD) courses will be of great help to improve KAP of healthcare providers 
towards nutrition.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all healthcare stakeholders, including clinical experts. In the past, clinical 
guidelines were developed independent of cost or economic considerations. However, 
increasingly, more clinical guidelines are mentioning cost concerns and referring to 
economic data in new recommendations. The objective of this study was to ana-
lyze trends in the use of health economic information for developing clinical guide-
lines. Methods: A systematic literature search was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines published 
between 2003-2012 were included. For guidelines which met the search criteria, data 
was collected for the name of the authors, indication, year of publication, country/
region, and context of use of cost/economic evidence. Results: Sixteen clinical 
guidelines published between 2003-2014 met the inclusion criteria for specific men-
tion of cost/economic evidence. More than 50% of these guidelines were published 
between 2006-2014. For indication, 3 out of 16 guidelines were for diabetes, while 
the rest were for different indications. In these16 guidelines “cost effectiveness” was 
mentioned 14 times, either referencing cost-effectiveness data or to mention the 
importance of such data for selecting treatment options. The guidelines commonly 
cite high cost of disease or high economic burden as one of the considerations for 
developing new recommendations (11 out of 16). Another term that was commonly 
used by these guidelines was “cost-benefit,” which was mentioned 5 times in these 
guidelines. Notably, QALY was rarely mentioned (1 out of 16 times) in these guide-
lines. ConClusions: This analysis suggests that some clinical experts groups are 
increasingly showing willingness to use and incorporate health economic information 
for developing new recommendations. Findings from this study might aid drug and 
device manufacturers in understanding the context of use of such information and 
allow them to tailor their product development plans for generating such evidence.
HealtH care use & Policy studies – Quality of care
PHP168
effectiveness of interventions for druG PrescriBinG imProvement 
in Primary HealtH care
Zavala-González M.A., Cabrera-Pivaral C.E., Orozco-Valerio M.J.
University of Guadalajara, Guadalajara, Mexico
objeCtives: To determine effectiveness of interventions for drug prescribing 
improvement in primary health care units. Methods: Systematic review and 
meta-analysis. Was held a quest in MedLine©, ScienceDirect©, Springer©, SciELO©, 
Dialnet©, RedALyC© and Imbiomed©, since indexation date of each database until 
August 2014. Were utilized keywords “drug prescribing”, “intervention studies” and 
“primary health care” with your synonyms. Were included quantitative studies, 
experimental and quasi-experimental, wrote in Spanish, English or Portuguese, 
and published in any country, with CASP-score equal or major than five, where 
drug-prescribing quality was evaluated accord to physicians’ adherence to drug 
posology and mexican guidelines for diseases treatment. Were excluded stud-
ies without raw data, qualitative studies, systematic reviews, protocols, essays, 
government documents, non-pharmacologic or alternative treatment studies 
and gray literature. Odds ratios (OR) with 95% interval confidence (p≤ 0,05) were 
obtained. Results: Were found 522 publications, were excluded 405 for title, 
99 for abstract and 9 for full text. Were included 3 references of the references. 
Don’t found references’ citations. Were analyzed 12 articles that reported 17 inter-
ventions: 64,7% educative, 23,5% incorporating of degreed in pharmacy to the 
health team, and 11,8% software utilization. The association forces “intervention/
improvement” obtained were: educative interventions OR= 2,47 (IC95% 2,28, 2,69), 
incorporating of degreed in pharmacy to the health team OR= 3,28 (IC95% 2,58, 
4,18), and software utilization OR= 10,16 (IC95% 8,81, 11,71). ConClusions: The 
software utilization interventions showed major effectiveness for to improve-
ment drug prescribing quality, versus educative interventions and incorporation 
of degreed in pharmacy to the health team. However, educative interventions may 
have a better cost-benefit relationship.
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objeCtives: Hungary runs a compulsory, solidarity based health insurance based 
system with a single payer. However, there is an increasing market of voluntary 
health insurance schemes and funds. The aim of this study is to analyze the vol-
untary health insurance market in Hungary. Methods: Our analysis is based on 
annual data from 2002 to 2013. The analysis of the number of funds and membership 
figures is based on end of the year data, the analysis of services and payments is 
based on annual data. We performed time series analysis and calculated dynamic 
